≡ Risteys
R14

Documentation Changelog GitHub Contact & Feedback

Malignant neoplasm of thymus, including Hilmo

Endpoint Browser PheWeb

C3_THYMUS_WIDE

Endpoint definition

↥

Report an error or suggest an improvement for this endpoint codes

Endpoint definition steps

FinnGen

Phenotype data

557745

1. Apply sex-specific rule

None

557745

2. Check conditions

None

557745

3. Check pre-conditions, main-only, mode, registry filters

Registry filters:

  • Hospital discharge: ICD-10 — C37&
  • Hospital discharge: ICD-9 — 1640
  • Cause of death: ICD-10 — C37&
  • Cause of death: ICD-9 — 1640
  • Cancer registry: Topography ICD-O-3 — C37
  • Cancer registry: Morphology ICD-O-3 — ANY
  • Cancer registry: Behaviour codes — 3

3 out of 7 registries used, show all original rules.

174

4. Check minimum number of events

None

174

5. Include endpoints

None

174

6. Filter based on genotype QC (FinnGen only)

151

Control definitions (FinnGen only)

Control exclude
C3_CANCER, C3_CANCER_WIDE

Extra metadata

First used in FinnGen datafreeze
DF12

Case counts by codes

↥

FinnGen case counts by registry codes:

generic upset plot

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

This endpoint is excluded (different definition than used in FinnGen).

-FinnGen-

Key figures

All Female Male
Number of individuals 151 75 76
Unadjusted period prevalence (%) 0.03 0.03 0.03
Median age at first event (years) 63.73 64.06 63.41

-FinnGen-

Age distribution of first events

-FinnGen-

Year distribution of first events

-FinnGen-

Cumulative Incidence Function

No data

CodeWAS

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.

Matched cohort

Matched cases
162
Matched controls
1620
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
C37
ICD-10 Finland
Malignant neoplasm of thymus
+∞
96.8
83
*
D38.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Mediastinum
+∞
81.2
71
*
R91
ICD-10 Finland
Abnormal findings on diagnostic imaging of lung
20.8
77.5
72
60
D38.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Thymus
+∞
67.5
60
*
GEC24
NOMESCO Finland
Thoracoscopic thymectomy
816.5
59.7
55
*
GD1BD
NOMESCO Finland
Thorax extensive CT-examination
20.4
53.2
45
30
130
Kela drug reimbursment
Malignant tumour
+∞
53.1
48
*
D15.0
ICD-10 Finland
Benign neoplasm: Thymus
+∞
47.2
43
*
GD1AD
NOMESCO Finland
Thorax CT examination
15.5
44.9
44
38
H02AB02
ATC
dexamethasone; systemic
145.1
42.1
43
*
GEC23
NOMESCO Finland
Transsternal thymectomy
+∞
39.2
36
*
A03FA01
ATC
metoclopramide; systemic, rectal
8.7
38.3
64
113
JN4BD
NOMESCO Finland
Extensive body CT
15.1
37.2
36
30
8580/3-C37.9
ICD-O-3
Thymoma, NOS, of thymus
+∞
34.6
32
*
WD125
NOMESCO Finland
Demanding cystostatic therapy of methastized malignancy
+∞
33.5
31
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
8.5
32.9
129
511
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
7.1
32.7
69
153
8582/3-C37.9
ICD-O-3
Thymoma, type AB of thymus
+∞
31.3
29
*
JN4AD
NOMESCO Finland
Body CT examination
9.8
27.6
36
46
C79.8
ICD-10 Finland
Secondary malignant neoplasm of other specified sites
+∞
26.8
25
*
WF003
NOMESCO Finland
Adjuvant radiotherapy
+∞
26.8
25
*
WF049
NOMESCO Finland
Radiotherapy of metastasis
+∞
24.6
23
*
WX408
NOMESCO Finland
General anesthesy, balanced
5.3
24.3
73
216
XX3DW
NOMESCO Finland
Time consuming IT work
10.5
24.1
29
33
WF002
NOMESCO Finland
Radical radiotherapy
93.4
22.3
24
*
A04AA01
ATC
ondansetron; systemic, rectal
31.8
22.3
29
11
GD1CT
NOMESCO Finland
Biopsy of the lung with CT guidance
133.1
22.2
23
*
A04AA02
ATC
granisetron; systemic, transdermal
252.7
22.2
22
*
N02AA05
ATC
oxycodone; systemic
5.7
21.2
49
114
D38.1
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Trachea, bronchus and lung
126.4
21.1
22
*
L03AA13
ATC
pegfilgrastim; parenteral
239.5
21.1
21
*
ZXC96
NOMESCO Finland
Robot assisted procedure
239.5
21.1
21
*
WF004
NOMESCO Finland
Palliative radiotherapy
+∞
20.2
19
*
YG1BD
NOMESCO Finland
Extensive CT examination of thorax for dose design of radiotherapy
+∞
20.2
19
*
B01AB05
ATC
enoxaparin; parenteral
4.5
19.7
78
279
ZX012
NOMESCO Finland
Radiotherapy with large shaped fields - isocentric therapy
213.7
19.0
19
*
ZX120
NOMESCO Finland
Intravenous
7.9
18.5
28
42
G70.0
ICD-10 Finland
Myasthenia gravis
106.9
18.0
19
*
N07AA02
ATC
pyridostigmine; systemic
71.2
17.1
19
*
GD5BD
NOMESCO Finland
Thorax and upper abdomen combined extensive CT examination of
100.6
16.9
18
*
WZC00
NOMESCO Finland
Treatment plan or consultation
4.0
16.9
77
299
UGC12
NOMESCO Finland
Flexible bronchoscopy
7.0
16.7
28
47
WX302
NOMESCO Finland
Thoracal epidural anesthesy
28.0
16.5
22
9
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
5.5
16.4
37
83
A04AA55
ATC
palonosetron, combinations; systemic
+∞
15.9
15
*
C61
ICD-10 Finland
Malignant neoplasm of prostate
+∞
15.9
15
*
GEB30
NOMESCO Finland
Mediastinotomy and excision of lesion
+∞
15.9
15
*
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.0
15.6
64
229
Z51.5
ICD-10 Finland
Palliative care
13.3
15.5
27
24
TPH07
NOMESCO Finland
Cathetrisation of artery
5.3
15.1
35
80
108
Kela drug reimbursment
Myasthenia gravis
88.3
14.9
16
*
WZC30
NOMESCO Finland
Teaching
4.7
14.8
41
109
8140/3-C61.9
ICD-O-3
Adenocarcinoma, NOS, of prostate gland
+∞
14.8
14
*
WX402
NOMESCO Finland
General anaesthesia
4.0
14.7
56
189
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
+∞
13.7
13
*
A49.9
ICD-10 Finland
Bacterial infection, unspecified
5.2
13.5
31
70
R4110
NOMESCO Finland
Physiotherapy
3.5
13.0
65
261
TPH04
NOMESCO Finland
Cathetrisation of vein
3.7
12.9
54
193
ZX070
NOMESCO Finland
Intensity modified radiotherapy
+∞
12.7
12
*
L01BC06
ATC
capecitabine; oral
+∞
12.7
12
*
L03AA02
ATC
filgrastim; parenteral
140.4
12.6
13
*
N02AB03
ATC
fentanyl; nasal, sublingual, transdermal
32.8
11.9
15
5
Z51.1
ICD-10 Finland
Chemotherapy session for neoplasm
+∞
11.6
11
*
XZZ00
NOMESCO Finland
Active surveillance of a diagnosed cancer
+∞
11.6
11
*
8581/3-C37.9
ICD-O-3
Thymoma, type A of thymus
+∞
11.6
11
*
C38.1
ICD-10 Finland
Malignant neoplasm: Anterior mediastinum
+∞
11.6
11
*
J90
ICD-10 Finland
Pleural effusion, not elsewhere classified
17.1
11.1
17
11
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
3.1
11.1
71
325
GD5AD
NOMESCO Finland
Thorax and upper abdomen combined CT examination of
30.4
10.9
14
5
B01AB04
ATC
dalteparin; parenteral
9.9
10.7
21
24
C78.0
ICD-10 Finland
Secondary malignant neoplasm of lung
+∞
10.5
10
*
A04AD12
ATC
aprepitant; systemic
+∞
10.5
10
*
YG1AD
NOMESCO Finland
CT examination of thorax for dose design of radiotherapy
+∞
10.5
10
*
L01CB01
ATC
etoposide; systemic
+∞
10.5
10
*
116
Kela drug reimbursment
Prostate cancer
+∞
10.5
10
*
D15.2
ICD-10 Finland
Benign neoplasm: Mediastinum
+∞
10.5
10
*
XG412
NOMESCO Finland
Flow-volume spirometry with bronchospasmolysis
5.6
10.4
21
42
WX892
NOMESCO Finland
Monitored bed care
4.9
10.2
24
55
ZXE20
NOMESCO Finland
More than three and less than five hours
3.8
9.8
34
105
WX602
NOMESCO Finland
Repeated or continuing anesthesia shots throug a catheter
5.7
9.6
19
37
8585/3-C37.9
ICD-O-3
Thymoma, type B3 of thymus
+∞
9.5
9
*
8070/3-C37.9
ICD-O-3
Squamous cell carcinoma, NOS, of thymus
+∞
9.5
9
*
JN6AD
NOMESCO Finland
CT of torso and neck
25.7
9.0
12
5
L02AE02
ATC
leuprorelin; implant, parenteral
52.9
8.8
10
*
ZX090
NOMESCO Finland
Other technic of radiotherapy
94.8
8.5
9
*
J01MA12
ATC
levofloxacin; systemic
3.2
8.4
41
157
8583/3-C37.9
ICD-O-3
Thymoma, type B1 of thymus
+∞
8.4
8
*
WD105
NOMESCO Finland
Cystostatic therapy of methastized malignancy
+∞
8.4
8
*
GAA31
NOMESCO Finland
Thoracoscopy
+∞
8.4
8
*
WD405
NOMESCO Finland
Simple antiboidy therapy of methastized malignancy
+∞
8.4
8
*
WD115
NOMESCO Finland
Multiple cystostatic therapy of methastized malignancy
+∞
8.4
8
*
D48.7
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Other specified sites
+∞
8.4
8
*
R50.9
ICD-10 Finland
Fever, unspecified
3.4
8.3
34
117
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
4.3
8.0
22
57
A02BC02
ATC
pantoprazole; systemic
2.9
7.8
124
859
N03AX16
ATC
[U] pregabalin
2.8
7.7
49
217
ZXE03
NOMESCO Finland
Procedure duration 20 to 29 minutes
6.6
7.7
19
32
WB103
NOMESCO Finland
Simple adjuvant cytostatic therapy
+∞
7.3
7
*
JN4JR
NOMESCO Finland
Whole body extensive metabolic PET with CT
+∞
7.3
7
*
GD1CG
NOMESCO Finland
Extensive examination of lungs and pleura with high intensity magnet
+∞
7.3
7
*
8584/3-C37.9
ICD-O-3
Thymoma, type B2 of thymus
+∞
7.3
7
*
WD325
NOMESCO Finland
Demanding therapy of methastized malignancy with biomodifiers
+∞
7.3
7
*
GE1CT
NOMESCO Finland
Mediastinal biopsy with CT guidance
+∞
7.3
7
*
TPX10
NOMESCO Finland
Implantation of vascular injection port
21.2
7.2
10
5
ZXE04
NOMESCO Finland
Procedure duration 30 to 39 minutes
4.6
7.2
18
43
WW500
NOMESCO Finland
Blood transfusion
12.8
7.2
12
10
N02AX02
ATC
tramadol; systemic, rectal
2.4
7.0
84
500
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
6.7
7.0
17
28
XW000
NOMESCO Finland
Bone marrow biopsy
11.7
6.9
12
11
FB1BD
NOMESCO Finland
Extensive CT examination of arteria pulmonalis
4.1
6.9
20
54
HA1AE
NOMESCO Finland
Ultrasound examination of mammary glands
8.4
6.8
14
18
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
6.5
6.5
16
27
TPH30
NOMESCO Finland
Insertion of central venous catheter through periferal vein
72.6
6.5
7
*
C79.5
ICD-10 Finland
Secondary malignant neoplasm of bone and bone marrow
+∞
6.3
6
*
C38.3
ICD-10 Finland
Malignant neoplasm: Mediastinum, part unspecified
+∞
6.3
6
*
YX9AD
NOMESCO Finland
Other CT eamination for dose design of radiotherapy
+∞
6.3
6
*
M32.9
ICD-10 Finland
Systemic lupus erythematosus, unspecified
+∞
6.3
6
*
8090/3-C44.9
ICD-O-3
Basal cell carcinoma, NOS, of skin, NOS
+∞
6.3
6
*
115
Kela drug reimbursment
Breast cancer
+∞
6.3
6
*
C78.7
ICD-10 Finland
Secondary malignant neoplasm of liver and intrahepatic bile duct
+∞
6.3
6
*
A79
ICPC
Malignancy NOS
+∞
6.3
6
*
WB121
NOMESCO Finland
Demanding neoadjuvant cytostatic therapy
+∞
6.3
6
*
WB113
NOMESCO Finland
Multiple adjuvant cytostatic therapy
+∞
6.3
6
*

LabWAS

↥
OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
67
29
38.69
97.98
1.9
1.2
—
—
—
0
0
44
67
8.64
29.33
3.2
1.7
2.26
2.35
ug/l
0.13
32
53
106
384
6.09
28.63
3.4
2.0
—
—
—
0
0
108
406
5.98
27.68
10.0
5.1
—
—
—
0
0
132
643
6.69
23.47
11.6
12.7
1.11
1.25
inr
3.24
110
534
140
721
7.93
23.24
20.4
6.3
3.91
4.16
e9/l
0.88
124
625
39
67
7.35
23.06
11.5
9.6
26.02
25.26
mmol/l
0.53
39
67
122
588
5.35
21.04
3.7
2.3
—
—
estimate
—
0
0
130
669
5.77
20.35
10.7
5.3
0.61
0.56
e9/l
1.35
111
574
87
333
4.48
20.18
5.4
3.6
—
—
—
0
0
130
675
5.69
19.95
10.7
5.3
0.04
0.04
e9/l
0.82
111
581
131
685
5.77
19.91
10.8
5.3
1.66
1.83
e9/l
0.56
113
606
82
303
4.46
19.90
7.2
3.2
90.24
88.15
%
0.31
82
297
132
697
5.83
19.75
12.0
5.4
0.15
0.20
e9/l
3.45
114
608
44
104
5.44
18.53
1.4
1.0
—
—
—
0
0
96
415
4.22
18.40
2.6
1.6
—
—
—
0
0
123
635
4.89
18.38
13.5
6.0
1.20
1.21
mmol/l
0.31
113
557
37
78
5.85
17.61
17.8
10.9
0.59
0.69
%
0.82
37
78
56
169
4.54
17.46
13.7
6.7
104.29
104.20
mmol/l
0.05
56
169
91
390
4.04
17.41
13.9
4.0
—
—
—
0
0
37
80
5.70
17.12
1.2
1.6
—
—
—
0
0
53
157
4.53
16.87
13.4
8.0
13.68
11.21
kpa
1.79
53
152
53
157
4.53
16.87
13.4
8.1
7.42
7.42
ph
0.11
19
95
53
157
4.53
16.87
13.4
8.0
5.51
5.20
kpa
1.47
53
151
37
82
5.55
16.64
17.8
10.6
1.05
1.47
%
1.56
37
82
41
105
4.89
15.55
17.2
8.6
—
—
—
0
0
36
90
4.86
13.97
2.8
1.9
65.55
67.43
g/l
0.74
36
83
17
5
37.68
13.80
5.4
2.0
4.78
5.40
nmol/l
—
17
5
49
164
3.85
12.87
1.3
1.5
—
—
—
0
0
106
585
3.35
12.28
19.4
8.9
0.00
0.00
e9/l
0.48
86
472
79
373
3.18
11.86
6.9
3.0
7.40
7.40
ph
0.06
59
259
84
412
3.16
11.78
9.8
1.9
2.36
2.35
mmol/l
0.23
79
366
53
199
3.47
11.58
1.7
1.9
—
—
—
0
0
74
355
3.00
10.53
3.9
2.8
0.19
0.38
e6/l
1.10
60
249
46
168
3.43
10.39
2.3
2.4
21.84
24.62
%
0.63
46
157
52
206
3.24
10.29
3.8
2.8
4.77
3.14
e6/l
0.28
33
90
73
356
2.91
9.97
1.4
1.4
—
—
—
0
0
47
181
3.25
9.69
2.3
1.9
—
—
—
0
0
40
141
3.44
9.49
1.2
1.6
—
—
—
0
0
79
417
2.75
9.09
3.9
2.9
70.12
36.01
e6/l
0.46
66
308
85
477
2.65
8.50
4.8
3.6
79.80
61.88
e6/l
0.13
66
321
19
44
4.76
7.92
1.9
1.8
1.29
1.38
ug/l
0.03
19
38
7
0
+∞
7.34
2.1
0.0
20.29
—
u/ml
—
7
0
11
7
16.72
7.34
2.2
1.0
12.91
11.14
%
—
11
7
58
292
2.54
7.00
2.2
1.7
1.13
1.05
mg/l
0.13
48
229
11
8
14.63
7.00
2.8
1.9
31.95
52.06
%
—
11
8
56
280
2.53
6.83
2.4
2.3
3.38
5.22
e6/l
1.05
51
256
10
7
15.11
6.48
1.0
1.7
—
—
—
0
0
61
324
2.42
6.48
1.9
2.0
2.99
2.74
mg/l
0.32
54
276
48
229
2.56
6.41
2.2
2.7
534.29
546.99
mosm/kgh2o
0.14
42
199
40
187
2.51
5.50
1.3
1.4
733.33
560.98
titre
0.35
12
41
8
5
16.71
5.47
3.0
1.0
26.50
331.60
e6/l
—
8
5
154
1337
4.07
5.21
36.2
12.6
32.13
23.67
mg/l
2.59
149
1050
8
6
13.93
5.13
2.3
1.0
—
—
—
0
0
32
140
2.60
5.02
2.3
2.0
6.62
9.36
umol/l
0.41
32
124
22
80
3.02
4.84
3.4
1.4
—
—
—
0
0
7
5
14.54
4.62
2.1
1.4
—
—
—
0
0
67
422
2.00
4.33
3.4
2.3
64.03
67.24
u/l
0.10
67
391
8
9
9.27
4.33
5.9
6.0
—
—
—
0
0
9
13
7.26
4.22
2.9
2.1
—
—
—
0
0
26
113
2.55
4.11
6.3
2.1
57.57
63.52
e9/l
0.39
17
79
136
1118
2.35
3.98
41.9
15.6
14.23
13.49
%
5.10
136
1108
34
173
2.22
3.80
2.7
1.5
—
—
—
0
0
156
1413
3.81
3.69
37.6
15.5
139.12
139.82
mmol/l
2.78
156
1386
97
718
1.87
3.68
4.0
3.5
0.04
0.00
estimate
0.48
23
133
22
93
2.58
3.67
1.6
1.3
31.51
337.73
u/ml
2.04
16
87
99
738
1.88
3.67
4.0
3.5
0.00
0.00
estimate
-0.00
23
128
29
140
2.31
3.66
5.6
3.4
7.37
7.38
ph
0.64
13
84
21
88
2.59
3.57
6.2
4.1
82.90
88.81
ng/l
0.11
21
79
81
571
1.84
3.55
4.4
3.5
40.29
37.55
ng/l
0.05
64
394
156
1415
3.76
3.53
37.9
15.5
3.94
3.97
mmol/l
0.97
156
1386
10
22
4.77
3.49
1.3
1.1
2.00
5.58
u/ml
—
5
12
97
728
1.83
3.42
4.0
3.5
0.00
0.00
estimate
-0.00
21
138
20
84
2.58
3.38
6.5
5.7
—
—
—
0
0
9
19
4.95
3.29
1.3
1.1
—
—
—
0
0
14
51
2.91
3.07
1.1
1.2
—
—
—
0
0
16
63
2.71
3.06
2.7
1.4
20.01
5.46
iu/ml
—
9
14
49
309
1.84
2.99
3.7
3.9
101.66
304.85
ng/l
1.06
41
245
8
17
4.89
2.96
1.9
1.1
—
—
—
0
0
8
17
4.89
2.96
1.9
1.1
—
—
—
0
0
8
17
4.89
2.96
1.9
1.1
—
—
—
0
0
8
17
4.89
2.96
1.9
1.1
—
—
—
0
0
45
277
1.86
2.95
1.2
1.3
743.06
27.34
iu/ml
0.48
14
83
9
22
4.27
2.93
7.2
2.8
—
—
—
0
0
46
287
1.84
2.89
2.0
1.3
2.13
2.58
g/l
1.05
37
168
55
367
1.75
2.75
2.9
3.2
—
—
—
0
0
78
580
1.67
2.60
3.7
3.2
6.22
6.26
ph
0.13
44
321
6
11
5.62
2.56
1.0
1.0
—
—
—
0
0
9
26
3.60
2.52
2.2
1.4
—
—
—
0
0
7
17
4.25
2.38
3.0
2.7
4.05
4.96
e9/l
—
7
17
7
17
4.25
2.38
1.4
1.2
—
—
—
0
0
20
99
2.16
2.38
4.6
3.9
0.30
0.20
%
—
5
20
14
59
2.50
2.36
5.4
2.1
—
—
—
0
0
26
145
1.94
2.27
1.8
1.7
—
—
—
0
0
9
29
3.22
2.26
1.2
1.1
—
—
—
0
0
44
292
1.70
2.20
9.0
4.3
—
—
—
0
0
20
104
2.05
2.11
5.5
4.3
0.00
0.00
%
—
5
16
7
20
3.61
2.08
3.0
2.6
60.43
58.75
%
—
7
20
156
1461
2.83
2.01
43.4
16.5
78.24
77.17
umol/l
0.16
156
1445
8
27
3.06
1.96
1.0
1.2
—
—
—
0
0
5
11
4.65
1.95
12.4
1.2
0.56
0.77
%
—
5
6
7
22
3.28
1.90
1.3
2.3
—
—
—
0
0
6
17
3.62
1.85
1.0
1.6
0.18
0.18
nmol/l
—
6
11
152
1406
2.31
1.85
24.6
11.5
—
—
—
0
0
53
386
1.55
1.79
4.3
3.5
0.00
0.01
estimate
0.50
18
123
6
18
3.42
1.76
2.0
2.4
4.95
5.12
kpa
—
6
18
6
18
3.42
1.76
1.2
1.3
—
—
—
0
0
6
18
3.42
1.76
2.0
2.4
8.75
8.31
kpa
—
6
18
8
30
2.75
1.75
1.3
1.2
—
—
—
0
0
5
13
3.93
1.73
1.2
1.8
8.48
12.35
%
—
5
13
22
128
1.83
1.71
3.3
2.0
0.00
0.00
estimate
—
6
23
5
14
3.65
1.62
1.0
1.6
—
—
nmol/l
—
0
0
6
20
3.07
1.59
1.3
1.9
—
—
—
0
0
12
58
2.15
1.53
1.3
1.8
—
—
—
0
0
5
15
3.40
1.53
3.0
1.4
181.86
28.71
ng/l
—
5
15
24
149
1.72
1.52
1.5
1.4
—
—
—
0
0
50
643
0.68
1.46
1.8
2.0
1.34
1.34
mmol/l
0.00
44
551
7
29
2.48
1.41
4.3
3.0
7.41
7.40
ph
—
7
29
133
1424
0.63
1.34
5.0
6.2
2.67
2.71
mmol/l
0.20
128
1339
18
107
1.77
1.32
1.2
1.3
—
—
—
0
0
6
24
2.56
1.31
1.0
1.0
—
—
—
0
0
35
249
1.52
1.30
1.3
1.4
2.12
8.03
u/ml
—
10
95
6
25
2.45
1.25
1.0
1.0
—
—
—
0
0
26
175
1.58
1.22
2.4
2.1
118.69
92.46
ug/g
0.25
26
141
10
50
2.07
1.19
1.8
1.1
44.01
24.61
iu/l
—
10
43
10
50
2.07
1.19
1.1
1.2
—
—
—
0
0
156
1496
2.15
1.10
51.1
19.6
130.05
137.89
g/l
7.51
156
1476
11
59
1.93
1.10
3.0
4.8
0.95
0.93
%
0.06
11
54
8
146
0.52
1.10
1.4
1.4
—
—
—
0
0
156
1495
2.17
1.10
50.9
19.6
6.67
6.57
e9/l
0.26
156
1460
156
1495
2.17
1.10
50.5
19.4
30.22
30.41
pg
0.68
156
1476
156
1495
2.17
1.10
50.8
19.5
255.63
246.65
e9/l
0.95
156
1466
156
1495
2.17
1.10
50.7
19.5
91.50
91.10
fl
0.51
156
1476
156
1495
2.17
1.10
53.7
19.9
39.16
40.97
%
3.85
156
1476
156
1495
2.17
1.10
50.7
19.5
4.38
4.56
e12/l
4.10
156
1461
5
21
2.42
1.10
1.4
1.3
—
—
—
0
0
17
106
1.67
1.08
2.6
4.1
206.71
181.79
ng/l
0.17
17
97
14
83
1.75
1.05
4.1
3.0
1.22
1.22
mmol/l
0.11
14
71
132
1403
0.68
1.03
4.4
5.2
1.44
1.45
mmol/l
0.17
127
1312
7
35
2.04
1.01
2.1
1.8
—
—
—
0
0
7
36
1.99
0.98
14.1
6.2
3.81
3.89
mmol/l
—
7
36
73
624
1.31
0.91
1.9
2.0
89.30
94.22
pmol/l
0.50
44
308
19
128
1.55
0.91
4.8
1.8
341.26
381.36
nmol/l
0.52
19
119
133
1405
0.70
0.89
4.5
5.4
4.60
4.62
mmol/l
0.08
127
1321
14
88
1.65
0.87
2.1
3.3
—
—
—
0
0
15
97
1.60
0.85
1.8
1.6
—
—
—
0
0
26
191
1.43
0.84
1.4
1.2
—
—
—
0
0
64
544
1.29
0.82
3.7
3.3
0.11
0.00
estimate
0.48
19
111
6
33
1.85
0.80
2.7
1.1
14.33
4.76
u/l
—
6
27
5
24
2.12
0.75
4.0
4.0
30.48
24.24
mg/l
—
5
17
47
388
1.30
0.74
2.8
3.0
0.00
0.00
estimate
-0.00
15
107
9
57
1.61
0.72
16.6
5.0
36.83
36.88
°c
—
9
57
11
69
1.64
0.70
4.6
2.3
0.63
0.57
%
0.24
11
69
7
43
1.66
0.67
1.0
1.2
387.29
455.09
mg/l
—
7
43
5
28
1.81
0.66
1.0
1.1
—
—
—
0
0
11
71
1.59
0.64
4.6
2.3
1.19
1.20
%
0.02
11
71
113
1051
1.25
0.61
4.2
3.9
15.28
14.72
pmol/l
1.37
106
965
11
73
1.54
0.58
1.7
1.6
0.26
0.48
mg/l
—
5
29
56
495
1.20
0.48
4.2
3.4
—
—
—
0
0
128
1332
0.81
0.44
3.8
4.5
1.29
1.30
mmol/l
0.06
123
1236
10
70
1.46
0.43
3.0
3.6
4.32
4.56
pmol/l
—
10
63
14
105
1.36
0.42
2.6
2.0
5.83
6.08
ph
—
9
71
0
16
0.00
0.41
0.0
2.3
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
173.20
—
0
16
0
18
0.00
0.40
0.0
1.4
—
—
—
0
0
5
35
1.44
0.39
1.0
1.7
—
5.53
—
0
15
9
67
1.36
0.39
1.1
1.3
—
—
—
0
0
8
113
0.69
0.38
1.3
1.2
—
—
—
0
0
51
566
0.86
0.37
2.8
3.4
—
—
—
0
0
141
1367
1.24
0.36
5.0
5.0
5.83
6.00
mmol/l
1.11
133
1271
17
137
1.27
0.33
1.3
1.3
—
—
—
0
0
12
92
1.33
0.33
1.8
1.5
—
49.68
—
0
13
0
10
0.00
0.21
0.0
9.5
—
0.63
—
0
10
0
13
0.00
0.21
0.0
1.0
—
—
—
0
0
0
13
0.00
0.21
0.0
1.5
—
9.05
—
0
13
36
337
1.09
0.13
4.1
3.6
1.02
1.02
kg/l
0.40
26
216
30
322
0.92
0.12
1.3
1.3
1.17
0.94
u/ml
—
10
86
49
511
0.94
0.10
3.6
3.4
53.66
49.79
mg/l
0.05
35
337
7
66
1.06
0.08
2.1
2.4
—
—
—
0
0
8
93
0.85
0.07
1.0
1.1
—
—
—
0
0
30
286
1.06
0.06
3.5
2.7
0.88
0.73
ug/l
0.39
22
168
14
148
0.94
0.02
1.6
1.6
—
—
—
0
0
51
517
0.98
0.01
4.0
4.1
9.55
7.55
mg/mmol
0.16
32
337
11
116
0.94
0.01
1.4
1.4
—
—
—
0
0
0
5
0.00
0.00
0.0
11.2
—
4.92
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
10.2
—
26.20
—
0
5
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
1.0
—
45.80
—
0
5
0
9
0.00
-0.00
0.0
1.2
—
179.52
—
0
9
5
53
0.94
-0.00
1.4
1.1
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.5
—
1.50
—
0
6
0
7
0.00
-0.00
0.0
1.1
—
88.79
—
0
7
0
7
0.00
-0.00
0.0
1.0
—
—
—
0
0

Mortality – FinRegistry

↥

This endpoint is excluded (different definition than used in FinnGen).

Relationships between endpoints

↥

Index endpoint: C3_THYMUS_WIDE – Malignant neoplasm of thymus, including Hilmo

GWS hits: -

This endpoint is excluded (different definition than used in FinnGen).